Litcius/Paper detail

Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis

Stephanie Taha‐Mehlitz, Gaia Bianco, Mairene Coto‐Llerena, Venkatesh Kancherla, Glenn R. Bantug, John Gallon, Caner Ercan, Federica Panebianco, Serenella Eppenberger‐Castori, M. Strauß, Sebastian M. Staubli, Martin Bolli, Ralph Peterli, Matthias S. Matter, Luigi Terracciano, Markus von Flüe, Charlotte K.Y. Ng, Savas D. Soysal, Otto Kollmar, Salvatore Piscuoglio

2021Theranostics42 citationsDOIOpen Access PDF

Abstract

Our results suggest that ADSL is a novel oncogene in CRC, modulating mitochondrial function, metabolism and oxidative stress, thus promoting cell cycle progression, proliferation and migration. Our results also suggest that ADSL is a predictive biomarker of response to 6-mercaptopurine in the pre-clinical setting.

Topics & Concepts

PI3K/AKT/mTOR pathwayColorectal cancerCancer researchMitochondrionCancerChemistryBiologyMedicineCell biologySignal transductionGeneticsBiochemical and Molecular ResearchCancer, Hypoxia, and MetabolismColorectal Cancer Treatments and Studies
Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis | Litcius